Skip to content

Glucosamine Sulphate and Ginkgo Biloba as Antifungal Activity for Treating Tinea Pedis

Glucosamine Sulphate and Ginkgo Biloba for Treating Tinea Pedis

Status
UNKNOWN
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02882438
Enrollment
30
Registered
2016-08-29
Start date
2016-01-31
Completion date
2022-10-31
Last updated
2019-10-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Foot Infection Tinea Pedis

Brief summary

Tinea Pedis infected the feet of about 20-25% of the world population. Tinea Pedis is a fungal infection of the feet and it is easily spread. Oral therapy is usually used for chronic conditions or when topical treatment has failed. The aim of this study is to prove the antifungal and antibacterial activity of Ginko Biloba (GKB) & Glucosamine (GL) as separate material or both in combination.

Detailed description

Ginko Biloba (GKB) & Glucosamine (GL) were formulated in different dosage forms such as capsules, hydrogel and spray. GKB&GL were in filled in hard gelatin capsules as three formulae (GKB caps, GL caps and both as mixture in caps). Also, GKB&GL were formulated in hydrogel using 2% carbopol 934 as three formulae (GKB only, GL only and both as mixture). The same also were formulated as spray using alcohol, water and glycerol in concentration of 60%, 20% and 20% respectively. The study included 5 trials, involving 35 participants. The oral formulae were tried on 30 participants having Tenia Pedis. Fluconazole was as standard antifungal drug.The antifungal activity of all gel formulae was determined by Agar well-diffusion method. It is also important to follow up and collect data, preferably for six months for local and systemic activity, to establish whether or not the infection recurred or not. In future clinical trials, research should consider the costs of the different treatment approaches.

Interventions

DRUGinfected group

Ginkgo Biloba in different dosage forms

DRUGcontrol group

placebo without Ginkgo Biloba

Sponsors

Ahmed A. H. Abdellatif
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
20 Years to 40 Years
Healthy volunteers
Yes

Inclusion criteria

* It is important to follow up and collect data, preferably for six months for local and systemic activity of Ginkgo Biloba and Glucosamine, to establish whether the infection recurrent or not.

Exclusion criteria

* Larger numbers of participants having different kind of fungal infection are needed to test efficiency drug in order to produce more reliable data.

Design outcomes

Primary

MeasureTime frameDescription
Assessment the antifungal activity of Ginkgo Biloba & Glucosaminesix monthsGinkgo Biloba and Glucosamine will be applied with infected patients even systemically or topically. The results will be compared with control groups to prove the Antifungal Activity.

Secondary

MeasureTime frameDescription
Stability test for different dosage formsthree monthsStability test will be studied for dosage forms. The test will carried out by standing the products on shelf life for three months. The stability test will be recorded using high performance liquid chromatography each thee days.

Countries

Egypt

Contacts

Primary ContactAhmed A. H. Abdellatif, phD
ahmed.a.h.abdellatif@azhar.edu.eg+201016660069

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026